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Electrical stimulation of the auricular vagus nerve (aVNS) is an emerging electroceutical
technology in the field of bioelectronic medicine with applications in therapy. Artificial
modulation of the afferent vagus nerve – a powerful entrance to the brain – affects a large
number of physiological processes implicating interactions between the brain and body.
Engineering aspects of aVNS determine its efficiency in application. The relevant safety
and regulatory issues need to be appropriately addressed. In particular, in silico modeling
acts as a tool for aVNS optimization. The evolution of personalized electroceuticals
using novel architectures of the closed-loop aVNS paradigms with biofeedback can
be expected to optimally meet therapy needs. For the first time, two international
workshops on aVNS have been held in Warsaw and Vienna in 2017 within the scope
of EU COST Action “European network for innovative uses of EMFs in biomedical
applications (BM1309).” Both workshops focused critically on the driving physiological
mechanisms of aVNS, its experimental and clinical studies in animals and humans,
in silico aVNS studies, technological advancements, and regulatory barriers. The results
of the workshops are covered in two reviews, covering physiological and engineering
aspects. The present review summarizes on engineering aspects – a discussion of
physiological aspects is provided by our accompanying article (Kaniusas et al., 2019).
Both reviews build a reasonable bridge from the rationale of aVNS as a therapeutic
tool to current research lines, all of them being highly relevant for the promising aVNS
technology to reach the patient.
Keywords: vagus nerve stimulation, auricular nerves, auricular transillumination, stimulation patterns, stimulation
optimization, in silico modeling, personalized stimulation
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INTRODUCTION
Bioelectronic medicine progressively comes into focus as a
non-pharmaceutical treatment option for various diseases. Here
neuromodulation of the vagus nerve (VN) gained a special
interest in recent years.
This review aims to summarize the contemporary views
on the electrical stimulation of the auricular VN (aVNS) as
a promising electroceutical therapy in humans. Catalysts were
the first two international workshops on aVNS in Warsaw
(February 16, 2017) and Vienna (October 26 and 27, 2017)
within the scope of EU COST Action “European network for
innovative uses of EMFs in biomedical applications (BM1309).”
In particular, the present review summarizes and discusses
technical issues, modeling concepts, regulatory and safety
requirements, and novel architectures of open and closed-loop
aVNS paradigms. A focussed review on the physiological role of
VN including a biology-driven rationale for aVNS is provided in
our accompanying article (Kaniusas et al., 2019).
We start with a short introduction on biophysical principles
underlying aVNS and continue with technological issues on
aVNS and the associated challenges from an engineering
point of view. Then we revise in silico modeling to optimize
aVNS technology and closed-loop aVNS to personalize
aVNS therapy. Future directions in aVNS are identified to
complement this review.
In short, VN plays a crucial role in sensing and regulating
bodily states while forming brain-body connections. The
complex anatomic and physiologic structure of VN yields
challenges in the engineering of effective aVNS devices. In
particular, specific fibers of VN determine their particular
signaling properties and projection sites, which require aVNS
to be tuned to specific stimulation patterns. These should
consider the degree of myelination of VN fibers – myelinated A
and B fibers intermingling with non-myelinated C fibers, their
associated excitability and direction of the information transfer.
Most VN fibers (about 80%) are afferent sensory fibers
carrying somatic and visceral information to the brainstem
and thus providing a unique entrance to the brain (Berthoud
and Neuhuber, 2001; Groves and Brown, 2005). As shown in
Figure 1A, most afferent fibers of VN end in the nucleus of
the solitary tract (NTS). The rest of VN fibers (about 20%) are
efferent visceromotor fibers governing neurogenic, myogenic,
and endocrine actions within projected organs.
From an engineering point of view, VN connects specific
sensors and effectors in the periphery with the central nervous
system. Mediated connections of VN include projections to
brain regions mediating homeostatic signaling and multisensory
integration and thus allowing a modulative access of VN to high-
level brain functions (Berthoud and Neuhuber, 2001). Therefore,
signals generated in VN have the potential to affect a broad range
of basic brain functions and thus to affect the entire organism of
the body in terms of its protection.
The external ear is an ideal place for a non-invasive or
minimally invasive stimulation of VN. In fact, the auricular
branch of VN surfaces as the auricular afferent VN (aVN) and
thus forms a cutaneous receptive field in the pinna of the ear.
Like VN, aVN is composed out of myelinated Aβ and Aδ fibers
(Safi et al., 2016) and non-myelinated C fibers (Standring, 2016).
The receptive field is susceptible to external stimuli in terms
of peripheral nerve stimulation. In particular, aVN is available
for an easy external access via electrical stimulation in terms of
aVNS, which then connects directly and favorably the applied
stimuli to the brainstem, as shown in Figure 1B. The auricle
and especially its aVN endings might become a powerful direct
gateway to the brain, offering the most affordable manipulation
of the central nervous system.
Since aVNS projects directly to NTS (Figure 1A), both
the autonomic and central nervous systems are modulated
by aVNS. Consequently, since the autonomic nervous system,
composed out of sympathetic and parasympathetic branches,
governs systemic parameters of cardiovascular, respiratory, and
immunological functions to stay within homeostatic limits and,
on the other hand, aVNS modulates the parasympathetic aVN,
aVNS effects on the body can be expected to be systemic.
Thus, aVNS is a peripheral, non-pharmacological, and
minimally invasive neuromodulation technique. Due to
systemic effects of aVNS – and, in general, of any vagus
nerve stimulation (VNS) – many different biophysical
mechanisms have been found to be modulated, as described
in our accompanying article (Kaniusas et al., 2019). In short,
aVNS alters signal processing in the central nervous system,
activates reflex circuitries, and exploits brain plasticity and
neural adaptation. The brain chemistry, nociceptive processing,
inflammation, and autonomic function are modulated for
different therapeutic purposes. Disease mitigating effects
and sustainable therapeutic applications range from chronic
pain diseases, neurodegenerative and metabolic ailments to
inflammatory and cardiovascular diseases, including modulated
psychometric functions.
ELECTRICAL STIMULATION OF VN
Invasive VNS Versus Non-invasive VNS
The targeted stimulation of the afferent VN, i.e., the translation
of artificial electrical impulses into natural action potentials
traveling into the brain, relays basically on four methods
considering invasive VNS, non-invasive VNS, non-invasive
aVNS, and minimally invasive aVNS:
(i) An invasive stimulation of VN can be performed via implanted
cuff electrodes at the cervical level wrapped typically around
the left cervical branch of VN (Mertens et al., 2018). The
invasive VNS typically uses a bipolar cuff electrode (e.g., VNS
Therapy, Cyberonics) with a bipolar stimulation pattern, either
with a fixed non-adaptive stimulation (e.g., 30 s ON and 5 min
OFF) or on-demand adaptive stimulation triggered by the
patient. The method is approved for epilepsy and depression.
Implantation risks and high costs are present, irreversibility
of the electrode implant, as well as infection-associated
morbidity. Unfortunately, implanted electrodes recruit not
only the targeted afferent fibers but also the (visceral) efferent
fibers of the mixed cervical VN branch (Howland, 2014).
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FIGURE 1 | Natural sensory innervation of the auricle versus its artificial stimulation. (A) The vagus nerve (VN) connects the brain with most of the organs within the
thorax and abdomen. Afferent auricular branches (aVN) leave the cervical VN at the level of the jugular ganglion just outside the cranium and innervate the rather
central regions of the pinna of the outer ear (Peuker and Filler, 2002). (B) Electric stimulation of aVN endings with needle electrodes located within these central
regions. NTS, nucleus of the solitary tract; NSNT, nucleus spinalis of the trigeminal nerve; NA, nucleus ambiguous; DMN, dorsal motor nucleus.
This unwanted stimulation of motor VN fibers leads to
unfavorable multiple side effects such as cough, voice alteration
(hoarseness), swallowing difficulties, or bradycardia, present in
up to 30% of patients (Liporace et al., 2001). These side effects
exclude application of strong and bilateral stimuli limiting
their potential efficacy (Mercante et al., 2018). Side effects are
incongruently reported either to increase during the time of
stimulation (Liporace et al., 2001) or decrease (Beekwilder and
Beems, 2010; Ben-Menachem et al., 2015).
(ii) The afferent branches of the cervical VN can also be non-
invasively stimulated via surface skin electrodes of a hand-held
device applied at the neck (Barbanti et al., 2015; Gaul et al.,
2016; Silberstein et al., 2016). The transcutaneous stimulation
uses two surface electrodes and is intermittently activated
(e.g., GammaCore, electroCore, Inc.), e.g., for 6 stimulation
sessions per day for in total 12 min, each session lasting 2 min.
The method is approved for migraine headache and episodic
cluster headache, as a preventive and/or acute treatment at
onset of attacks. In order to stimulate VN relatively deep under
the neck surface, the stimulation is performed using bipolar
bursts of a relatively high frequency of 5 kHz for the burst
duration of 1 ms, with a periodic bursting of 25 Hz (Gaul et al.,
2016). However, relatively strong currents are still required
to circumvent the skin barrier. Since the induced stimulation
fields in the neck are diffuse, a co-stimulation of cervical non-
vagal nerves and their local endings, as well as unintended
recruitment of efferent fibers with the associated adverse effects
can be expected. These side effects are prickling at stimulation
site, neck pain, dizziness, headache, nasopharyngitis, and
oropharyngeal pain (Gaul et al., 2016).
(iii) The receptive field of afferent aVN endings can
be stimulated via non-invasive surface skin electrodes on
the outer ear, known as transcutaneous aVNS (Ellrich,
2011; Straube et al., 2015). The transcutaneous aVNS uses
two surface electrodes and is intermittently activated (e.g.,
NEMOS, Cerbomed GmbH), e.g., for 3–4 stimulation sessions
per day for in total 4–5 h, each session lasting at least
1 h. The method is approved for epilepsy, depression,
pain, and migraine. Advantageously, only afferent VN endings
are stimulated, avoiding the aforementioned side effects of the
invasive VNS. However, as a possible disadvantage, relatively
large surface electrodes yield diffuse stimulation fields.
Therefore, not only vagal but also other non-vagal nerves in the
ear can be expected to be stimulated (Figure 1A), implications
of which are still controversial (see Stimulation Regions).
For instance, psychometric effects of the transcutaneous
aVNS were independent on the precise stimulation location
(Kothe, 2009), which highlights the diffuse regime of the
transcutaneous aVNS. In addition, relatively strong currents
and good electrode contacts are required for the current
stimuli to circumvent the skin barrier of the ear and still stay
suprathreshold in regions innervated by aVN. The stimulation
is safe (Badran et al., 2018b), the remaining side effects are
mostly minor – as related to invasive VNS – and may include
headache, pain and skin irritation at the stimulation site, and
dizziness (Mertens et al., 2018).
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(iv) A percutaneous minimally invasive aVNS (Kampusch
et al., 2013) can be performed with miniature needle electrodes
penetrating the skin in the targeted outer ear regions
innervated mainly by aVN (Figure 1). The percutaneous aVNS
typically uses 2–3 needle electrodes and is also intermittently
activated (e.g., AuriStim or P-Stim, Multisana GmbH). For
instance, an automatic duty cycle of 3 h ON and 3 h OFF
lasts for over 1 week, with a net stimulation time of 12 h
per 24 h. Thus, the percutaneous aVNS shows the longest net
stimulation time per day when compared with the invasive and
transcutaneous aVNS. The percutaneous aVNS is approved
for chronic cervical pain, chronic low back pain, migraine,
acute postoperative pain, and pain due to peripheral arterial
occlusive disease.
In contrast to the transcutaneous aVNS, the small size
of needle electrodes and the resulting spatially focussed
stimulating fields favor precise and specific stimulation of the
local afferent aVN endings, which avoids diffuse stimulation.
In addition, electrode contact impedance is lower and more
reproducible, favoring an energy-efficient stimulation. Minor
side effects of the percutaneous aVNS are local skin irritation
(dermatitis), local bleeding, pain at the stimulation side,
and dizziness. The clinical incidence of skin irritation and
inadvertent bleeding can be reduced down to only 0.05%
using a transillumination technique of the ear, which visualizes
auricular vessels to avoid random placement of needles and
thus reduces the potential of bleeding (Kampusch et al., 2016;
Roberts et al., 2016). Although stimulation devices use needle
electrodes and have to be worn over several days, more than
80% of patients are greatly satisfied with this treatment in
terms of their subjective perception on life quality, with absent
or only minor adverse effects (Kampusch et al., 2016).
A few indirect but rather seldom effects can also be
triggered by aVNS due to afferent-efferent vagal reflexes with
the vagal nucleus, NTS, as a potential intermediate stage.
The Arnolds ear-cough reflex is the most dominant reflex,
in which mechanical irritation/palpation of the auricular skin
with embedded aVN may cause cough. There are also other
reflexes as ear-gag reflex, ear-lacrimation reflex, ear-syncope
reflex (known also as auriculo-cardiac reflex), and vaso-vagal
reflex. These vegetative reflexes or reactions can occur with a
delay of a few seconds (Tekdemir et al., 1998) and with the
respective incidence up to a few percent in the general population
(Tekdemir et al., 1998; Ellrich, 2011; Napadow et al., 2012).
Syncope, tachycardia, bradycardia, paresthesia, vertigo, headache
may also occur in response to aVNS. Contraindications for
aVNS include immunocompromised patients (because of semi-
permanent needles in the ear), hemophilia, psoriasis vulgaris at
application site, the presence of a pacemaker or other active
implantable devices (to avoid interference with aVNS), and vagal
hypersensitivity.
In general, non-invasive and minimally invasive aVNS
methods show fewer side effects than implantable VNS, which
raises the potential number of patients who could benefit from
aVNS. aVNS targets to modulate specific functions of the
brain (Kaniusas et al., 2019) and thus to reach a maximum
therapeutic effect while minimizing side effects. Non-invasive
portable devices are relatively easy to apply and are cost effective
as related to implantable devices (Morris et al., 2016). Favorably,
motor VN fibers cannot be recruited in aVNS avoiding a lot
of potential inadvertent effects, which is in clear contrast to
the invasive VN stimulation. Interestingly, scarification and
cauterization of the outer ear was practiced earlier as a “gross
acupuncture” for healing purposes, as a forerunner for aVNS.
Optimization of Stimulation Settings in
aVNS
Basically, two optimization aims should be addressed by the
stimulation set-up of aVNS:
(i) The stimulation of vagally innervated regions of the ear
should be targeted when applying aVNS. On the other
hand,
(ii) the electrical stimulation should optimally recruit aVN
fibers close to the stimulation electrodes for a given
stimulation waveform and strength.
Stimulation Regions
The first aim can be practically addressed via the anatomical
map of the different auricular nerves (Figure 1A). aVNS is
typically performed in the cymba and cavity of concha, crus of
antihelix, and the inner tragus region of the ear, which were
found to be at least partly innervated by aVN (Alvord and
Farmer, 1998; Kandel et al., 2000; Peuker and Filler, 2002; He
et al., 2012). While the diffuse stimulation of the transcutaneous
aVNS does not allow a precise selection of stimulated regions,
a spatially focussed stimulation is favored by the percutaneous
aVNS with its miniature needles set in the anatomical regions
innervated by aVN.
A special recognition is required here on the recent
controversy on the true anatomical location of aVN and whether
the stimulation effects of aVNS are due to the recruitment of aVN
or other nerves. The literature on the definite innervation of the
auricle is very sparse and is usually based on often cited findings
in Peuker and Filler (2002). These findings unfortunately show
some inconsistencies with respect to aVN innervation regions
(Burger and Verkuil, 2018) and are based on only 14 ears of seven
human cadavers (Peuker and Filler, 2002), which may not reflect
anatomical variations of a wider population.
Auricular vagus nerve stimulation is usually performed at the
tragus or (cavum, cymba) concha. However, some approaches
cover larger areas of the auricle (Sator-Katzenschlager and
Michalek-Sauberer, 2007) with the potential – and even with the
targeted aim (Kovacic et al., 2017) – to stimulate concomitantly a
few more auricular nerves in addition to aVN. The co-stimulated
nerves are the great auricular nerve (with connections to the
spinal cord) and/or the auriculotemporal nerve (connecting to
the nucleus spinalis of the trigeminal nerve). For instance, tracing
of the transcutaneous stimulation at the tragus in rats labeled
mainly the dorsal horn of the cervical spinal cord and labeled
only sparsely NTS, the termination site of aVN (Figure 1A), as
reported recently in Mahadi et al. (2019).
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It is also discussed if the tragus includes aVN endings or
only non-aVN endings, such as the great auricular nerve and the
auriculotemporal nerve (Badran et al., 2018a; Burger and Verkuil,
2018). A potential recruitment of these nerves would suggest
that mechanisms may be involved for tragal stimulation beyond
those anticipated for the sole aVN stimulation. Potentially,
the afferent and concomitant stimulation of vagal and non-
vagal endings synergize each other. Only the cymba concha
was found so far to be solely innervated by aVN (Peuker and
Filler, 2002) with the associated maximum activation of vagal
projections in NTS during stimulation, as compared to tragus,
cavum concha, or earlobe stimulation (Yakunina et al., 2016).
However, the cymba concha offers some disadvantages in terms
of complexity of electrical stimulation by requiring to insert
and/or to hold an electrode against the concha, as opposed to
having to clip onto the tragus. These uncertainties impede a
proper interpretation of stimulation effects while an optimal
target for the auricular stimulation is still under debate (Badran
et al., 2018a; Burger and Verkuil, 2018).
Another important question here is how to find the individual
aVN fibers in the ear and thus optimal regions for needles
placement. In fact, aVN fibers and their bundles are too thin –
in the submillimetre range (<100 µm), see Figure 2C – to
be recognized visually by the unaided applicant’s eye. We have
proposed (Kaniusas et al., 2011) to find these fibers based
on the associated auricular blood vessels (Alvord and Farmer,
1998; Tilotta et al., 2008) since fibers and blood vessels are
wired together, often alongside one another (Carmeliet and
Tessier-Lavigne, 2005), even in the auricle (Razlighi et al., 2018).
Figures 2B,C illustrate the joint proliferation of auricular vessels
and nerves – based on episcopic images – with a separation
distance of up to about 200 µm in this example.
A special transillumination method was designed to visualize
auricular vessels to the applicant’s eye while making use of the
different optical properties of blood vessels and the surrounding
tissues (Kaniusas et al., 2011). In clinical practice, easily
discernible vessels (<500 µm in auricle) indicate to the physician
the most likely regions of local bundles of nerve fibers which
are indistinguishable to the human eye. Figure 2D illustrates
transilluminated ear with clearly visible auricular blood vessels.
Lastly, stimulation of the left or right aVN cannot be expected
to yield different physiological effects since afferent information
from both sides are centrally merged in the brainstem (Chen
et al., 2015). This is in clear contrast to the invasive cervical VNS
with dominant lateral effects, in which, for instance, the right side
stimulation recruits predominantly the sinoatrial node (e.g., with
the associated bradycardia) and the left side the atrioventricular
node. However, simultaneous activation of the left and right aVN
may potentially boost stimulation effects due to increased sensory
input to the brainstem.
Stimulation Patterns
The second aim with the optimal recruitment of aVN fibers
near electrodes is even less straightforward. The diffuse mode
of the transcutaneous aVNS per-se does hardly allow a targeted
optimisation of stimulation of particular aVN fibers, whereas
local over-stimulation and under-stimulation of fibers are
possible. This is in contrast to the percutaneous aVNS, in
which stimulation needles can be precisely positioned relative
to aVN fibers and thus the associated stimulation patterns may
be optimized more easily; of course, provided that individual
locations of aVN fibers are known.
Needles should reside close to the local aVN fibers or their
endings (Bermejo et al., 2017) to guarantee their suprathreshold
stimulation but not too close to avoid their cathodic block
[characterized by the inhibited propagation of excitation
(Kaniusas, 2019)]. Then the maximum recruitment efficiency can
be attained for a given stimulation pattern (Tarnaud et al., 2018).
In general, the thicker fibers are and the closer fibers are to the
stimulation electrode, the less is the required excitation stimulus;
in addition, myelinated fibers are excited more easily than non-
myelinated fibers of the same thickness. Furthermore, more than
one stimulation needle close to local aVN fibers can be expected
to increase the net number of stimulated aVN fibers and thus
to increase the net recruitment efficiency. The penetration depth
of needles should be in the range of 1 mm, as suggested by the
depth of auricular fibers under the skin (Bermejo et al., 2017;
Razlighi et al., 2018).
Auricular vagus nerve stimulation of a percept-matched
and subjectively comfortable intensity is preferred to reach
therapeutic target (Busch et al., 2012; Napadow et al., 2012)
which is a strong function of the stimulation pattern (Bald,
2010; Kaniusas, 2019). For instance, Deuchars et al. (2017) prefer
intensities which are slightly below the subjective perception
level. We hypothesize that a tingling sensation is necessary, in line
with numerous studies (Kothe, 2009; Ellrich, 2011; Garcia et al.,
2017; Sclocco et al., 2019). This is because the non-nociceptive
aVNS should recruit myelinated Aβ fibers in the ear responsible
for cutaneous mechanoreception and touch sensation, instead
of myelinated Aδ fibers for cutaneous pain and temperature
sensation. Advantageously, relatively thick Aβ fibers (with the
diameter 7–10 µm) can be easier recruited than relatively thin
Aδ fibers (2–5 µm).
In particular, the pain perception – accompanied typically
by unpleasant, pricking, or burning sensations – should be
avoided while stimulating (Ben-Menachem et al., 2015). Yuan
and Silberstein (2015) report aVNS stimulation intensity between
the patient’s detection threshold and the pain threshold in
order to activate myelinated fibers. Ellrich and Lamp (2005)
suggest that non-painful innocuous peripheral nerve stimulation
preferentially activates Aβ fibers but not Aδ nociceptive fibers.
The selectivity in the stimulation of Aβ and Aδ fibers
highly depends on the stimulation pattern, as supported
by the experimental evidence (Dietrich et al., 2008). Here
relatively high stimulation frequencies of 20–25 Hz are
required for the peripheral electrical stimulation of the
parasympathetic system, whereas low frequencies of 0.5–
10 Hz are required for sympathetic system. High frequencies
show narrow depolarizing half-period durations and thus
are only able to recruit easily excitable thick nerve fibers
(Kaniusas, 2019), such as myelinated Aβ fibers, which
may indirectly activate the parasympathetic system. In
contrast, wide depolarizing half-periods of low frequencies
are required to recruit thin nerve fibers, such as myelinated
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FIGURE 2 | Wiring of vessels and nerves in the ear for the percutaneous aVNS. (A–C) High-resolution episcopic images of a volume biopsy in the cymba conchae of
one male cadaver ear. Indicated blood vessels (in red) and nerves (green) reside apparently close to each other indicating their joint proliferation in the ear. (D) In
order to find local auricular nerve branches, the outer ear is transilluminated to localize and visualize easily discernable auricular vessels which are less transparent
than the surrounding tissue for green light. The visualized locations of vessels indicate the most likely regions of nerves, which serve for a personalized placement of
stimulation needles.
Aδ or non-myelinated C fibers, activating usually the
sympathetic system.
Different stimulation patterns are being used in aVNS. For
instance, the percutaneous aVNS uses typically monophasic
rectangular pulses every 1 s (1 Hz stimulation) with changing
polarity and the pulse width of 1 ms, with the possibility to
change settings (Kampusch et al., 2013). The pulse width usually
determines the type of fibers to be excited. That is, short pulses
recruit easily excitable thick fibers only while elongated pulses
recruit both thick and thin fibers (Kaniusas, 2019). For the
transcutaneous aVNS, authors in Badran et al. (2018b) show
that different stimulation parameters yield different responses in
the heart rate (systemic body parameter), whereas Polak et al.
(2009) use vagus somatosensory evoked potentials to optimize
parameters. It highlights the physiological and therapeutic
relevance of the selected stimulation parameters.
The efficiency of stimulation can be increased with bursted
stimulation (Martlé et al., 2014; Szabó et al., 2017); e.g., with
bursts of short pulses every second (Reilly and Diamant, 2011;
Kampusch et al., 2013; Kaniusas, 2019). A single or a few action
impulses triggered at the sensory aVN endings in response
to single electrical stimuli are less likely to influence systemic
regulation or brain activity (e.g., the sympathovagal balance),
rather than a rhythmic sequence of these impulses. This is
because gradual natural sensory information is coded as the
gradual temporal density of non-gradual impulses, likewise,
coded as the instantaneous frequency of impulses. On the other
hand, the brain with its very large number of neurons and its
sophisticated processing is not likely to respond reasonably to a
single or a few impulses but to a train of impulses.
Due to complex physiology of the body, continuous and
intermittent stimulation, as well as strong and moderate
stimulation, may even induce opposite physiological effects.
For instance, synergistic actions of both sympathetic and
parasympathetic systems were shown for continuous VNS
(e.g., 10 Hz stimulation with 0.1 ms rectangular pulses),
whereas antagonistic actions were demonstrated for intermittent
VNS (e.g., 10 s ON period followed by 50 s OFF period)
(Buchholz et al., 2014). Here, for instance, the continuous VNS
was suggested to produce strong bradycardia and increased
loading conditions of the heart, leading to compensatory
sympathetic reflexes. In contrast, the intermittent VNS was, on
average, not intense enough so that the parasympathetic VNS was
still able to antagonize the sympathetic system.
Obviously, VNS or aVNS should be optimized with respect
to the administered dose and duty cycle, whereas the ALARA
principle (“as low as reasonably achievable”) applies for a given
therapeutic indication. Favorably, VNS or aVNS should not
be chronic in order to attain sustainable therapeutic effects.
For instance, the activation of the anti-inflammatory response
required only a brief VNS stimulus and lasted for more
than 24 h (Olofsson et al., 2015). A sustained antinociceptive
effect of aVNS was also observed in chronic low back pain
for a 3 months follow-up after 6 weeks of treatment (Sator-
Katzenschlager et al., 2004). In addition, the time instance of
the stimulus with respect to inner body rhythms – such as heart
beat or respiration – seems to be of high relevance. Ground-
breaking experimental works in Brown and Eccles (1934) have
shown the timing relevance in VNS. The influence of the
timing between aVNS and respiration cycle was demonstrated
in healthy subjects (Sclocco et al., 2019), as well as in chronic
pelvic pain (Napadow et al., 2012), and migraine (Garcia et al.,
2017), showing that aVNS delivered during exhalation was
more efficient in brain, cardiovagal, and pain modulation than
inspiration-gated stimulation.
While applying energy to the body via aVNS, electrochemical
and metabolic stress factors have to be avoided (Kaniusas, 2019).
The electrochemical stress is due to irreversible electrochemical
reactions at the electrode/tissue boundary, potentially harming
biological tissue, and is proportional to the absolute current
level. This is in contrast to the metabolic stress as an integral
stress, which is due to axonal loss and demyelination, and is
proportional to the time integral of the stimulation current.
In order to avoid irreversible electrochemical reactions, charge-
balanced current stimulus is a necessary condition; however,
strictly speaking, the charge balance is not a sufficient condition
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due to ongoing inert diffusion processes of reactants and products
from/to the electrode/tissue boundary (Kaniusas, 2019).
REGULATORY ISSUES OF aVNS
DEVICES
Bringing a medical device, like an aVNS device, on the market
comes along with many requirements since the medical device
market is highly regulated. Requirements encompass research
and engineering issues, clinical studies, regulatory and business
issues. Even though these requirements vary for different types of
stimulators, common regulatory requirements apply for all types
of aVNS devices and thus deserve a short overview. Here we focus
on EU guidelines and do not intend to cover global regulatory
issues because of their diversity.
The medical device directive EU 93/42/EEC is the basis
regulatory document for the required CE certification of aVNS
devices in EU, for monitoring and reporting requirements as
well as registration duties of manufacturer. A new regulatory
framework, the Medical Device Regulation EU 2017/745 was
released in 2017 and will only apply in spring 2020 after a
transition period. In fact, CE certification is the trading passport
in EU and European free trade association countries. The
typical path for CE marking according to EU 93/42/EEC is
illustrated in Figure 3.
Auricular vagus nerve stimulation device has to meet the
essential requirements of the directive and fulfill the selected
conformity assessment, which depends on the risk classification
of aVNS device. The applicable risk classification specifies the
quality management system that has to be implemented by
manufacturer and the necessity of a notified body to control
the conformity. In particular, a percutaneous aVNS device can
be classified as “short term” (application for less than 30 days),
“surgically invasive” (due to needle electrodes in the ear), and
“active therapeutical” device (stimulation energy is applied),
which implies that it is a Class IIa medical product. The
following conformity assessment procedures are available for
manufacturers for a Class IIa product: (i) verification of every
device or a random sample of devices by the notified body,
(ii) production quality assurance, (iii) product quality assurance,
and/or (iv) a full quality assurance system.
The implementation of a risk management system is
mandatory, accompanies the whole life cycle of any aVNS
product, and serves as the input for development, design,
and manufacturing of aVNS device. For instance, the risk
management should guarantee that the exchange of energy with
the human body is not hazardous, taking into account the nature,
the density, and the site of the energy application. In addition, a
usability engineering process needs to be established to assess the
usability and possible use errors already during the development
of aVNS, which is important for the final validation of aVNS
device within the intended use or patients.
For state-of-the-art development and safety of aVNS device
and its conformance with essential requirements, harmonized
EU standards and guidelines shall be followed. Standards
include EN ISO 14971 (for risk management), EN ISO 13485
(implementation of quality management system), EN 60601-1
including collateral standards (medical device basic safety and
essential performance), EN 62366-1 (usability engineering),
and EN 62304 (medical device software). Guidelines include
MEDDEV 2.7/1 (for specification of a proper clinical evaluation)
as well as MEDDEV 2.12-1 and MEDDEV 2.12/2 (market
surveillance and vigilance). Many guidelines have been
implemented within the new Medical Device Regulation
and thus are now obligatory. Since aVNS device is body worn
in home healthcare environments, additional requirements and
limitations arise. Further requirements come from the required
traceability and post-market surveillance that must be established
to fulfill vigilance duties. National deviations in requirements
have to be considered when marketing aVNS.
For the certification procedure and clinical safety, a
rigorous clinical evaluation of aVNS device must be prepared
and regularly revised, including clinical studies and/or a
systematic literature review. Clinical evaluation can also be
based on equivalent and predicate devices, proving technical,
biological, and clinical equivalence with supporting data for
all clinical claims made. However, showing the conformity
by equivalence is getting less accepted. This can cause high
costs and delayed market entrance due to the necessity of
extensive clinical trials for each new derivative of aVNS
device. A post-market clinical follow up plan is required.
Side effects must be studied; for instance, the cardiac safety
of the transcutaneous aVNS was investigated in Kreuzer
et al. (2012), whereas most users were satisfied with the
application and wear ability of the percutaneous aVNS
(Kampusch et al., 2016).
Specific construction features of an aVNS device such as
the implemented medical device software introduce further
demands. Biocompatibility of the used materials, especially
needle electrodes for the percutaneous aVNS, must also be
proven. If aVNS device consists of several parts, e.g., separate
stimulator and needle electrodes, these parts may need individual
CE marking if supplied separately. In order to avoid harm to
the patient (ICNIRP, 1998) – in addition to medical treatment
effects – a risk analysis of electrode’s current densities higher than
2 mA/cm2 (EN 60601-2-10) has to be provided.
The notified body is needed for assessment of the technical
documentation including the clinical evaluation, regular
inspection of the quality management system, and, finally,
for granting the CE certificate (for three years). Any minor
or major findings during assessment or auditing have to be
corrected within a specific time frame, followed by a report and
a post-audit inspection. After a declaration of conformity is
issued, the product for aVNS can be marketed within the EU
after registration at each national level.
In summary, there is need for an appropriate regulatory
management covering the whole life-cycle of any aVNS product
to avoid failure in the conformity assessment and market entry.
Highly faceted regulatory issues can delay time-to-market of an
aVNS device and tremendously increase costs and workload for a
medical device company. Thus, an early contact with a notified
body already during development is recommended to prevent
potential failures in the regulatory assessment.
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FIGURE 3 | CE-related regulatory pathway of aVNS medical devices.
IN SILICO NUMERICAL aVNS
In order to optimize aVNS – or any neurostimulation approach –
numerical simulation of aVNS is a reasonable approach. The
simulation requires a step-wise coupled electromagnetic and
electrophysiological modeling. First, the distribution of the
electric field in tissue is calculated in response to an applied
electric stimulus; e.g., via current or voltage electrodes on the
auricular skin (Figure 1B). The resulting distribution takes
into account the particular anatomy of the ear and its tissue
heterogeneity in terms of varying local electrical properties of
the auricular tissue (its conductivity and permittivity); anisotropy
of tissue properties is also considered. Second, the local electric
fields, their gradients and dynamic – resulting along extracellular
spaces or trajectories of auricular axons and their endings – are
used for the neural simulation. That is, the induced fields are
used for the investigation of the non-linear response of axonal
membranes to the applied stimulus. The dynamics of the electric
field is tightly connected with the temporal characteristics of
the applied stimulus (e.g., with the pulse shape). For the neural
simulation, the physiological distribution density of fiber types in
the ear and their diameters as well as realistic fiber models are
required. For instance, myelinated fibers can be approximated
with the SENN model (Reilly and Diamant, 2011), the MRG
model (McIntyre et al., 2002), or the Sweeney model (Sweeney
et al., 1987). An integrated modeling with a feedback of the
neural excitation to the excitatory extracellular electric potential
is not reasonable since local action impulses with a typical
swing in the membrane voltage by about 100 mV change only
insignificantly the extracellular potential by 1–3 mV (Rattay,
1990). In short, electrical properties of tissues between electrodes
and nerves and, on the other hand, properties of neural structures
(fiber’s trajectories, type, and diameter) determine the physical
stimulation depth and thresholds of aVNS for arbitrary electrode
placement and stimulation waveform.
Effects of the electrode/tissue boundary have to be
numerically accounted for. In particular, needle electrodes
for the percutaneous aVNS act typically as polarizable electrodes,
whereas surface electrodes for transcutaneous aVNS can act
as non-polarizable electrodes. These different electrode/tissue
interfaces can be numerically considered using pre-processed
data as input into the electromagnetic modeling of aVNS.
Neurostimulation by an arbitrary number of active electrodes
in the ear (single or multiple electrodes, see Figure 4B) can be
numerically assessed. For instance, the concept of the activating
function and their superposition can be favorably used here
if continuous neuronal trajectories in the auricle are known
(Rattay, 1986, 1999). It states that the activating function –
proportional to the second derivative of the extracellular electric
potential along the nerve trajectory – is positive for the local
depolarization and is negative for the local hyperpolarization.
The activating function predicts the site of spikes initiation
for a given neuronal trajectory. Since the activating function
of each single electrode is subjected to a strong decrease with
y3 (Kaniusas, 2019), with y as the normal electrode distance
to the considered axon (Figure 4A), a distant electrode with
its y about three times of y of another near electrode can
be neglected, if both electrodes carry the same stimulation
current. Likewise, the distant electrode contributes only very
little to the geometrical superposition result of the relevant
activating functions. In contrast, discontinuous or bend neuronal
trajectories are subjected to end-mode or bend-mode excitation,
respectively (Kaniusas, 2019), which is particularly relevant in
view of numerous aVN endings in the ear.
Different models for transcutaneous and percutaneous aVNS
have been developed, which use multiple electrodes, consider
spatiotemporal electric fields, the geometry and properties
of embedded nerves (Kuhn et al., 2008; Samoudi et al.,
2017, 2019; Kaniusas, 2019). These models allow numerical
optimisation not only of an engineering aVNS solution (e.g.,
its electrode shape and the applied stimulation pattern) but
also of the electrophysiological impact (e.g., the percentage of
activated axons), and consequently of the potential therapeutic
outcome of aVNS.
In particular, the required number of used stimulation
electrodes for aVNS and the resulting spatial width of the current
distribution within the ear can be numerically optimized. While
monopolar aVNS offers the most diffuse stimulation with the
lowest excitation threshold, bipolar and tripolar aVNS sharpen
the stimulation focus but unfavorably increase the threshold
(Reilly and Diamant, 2011; Kaniusas, 2019). In fact, the diffusivity
should be potentially restricted to aVN regions in the ear
(Figure 1A) to avoid stimulation of non-vagal nerves in the ear
and to reach reproducible aVN-gated effects.
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FIGURE 4 | Numerical modeling of aVNS with three stimulation electrodes. (A) Basic model of the tripolar stimulation with surface current electrodes. A single
cathode carries the current i (=1 mA) and the two surrounding anodes i/2 each. The unmyelinated axon lays in parallel to electrodes at the depth of 2 mm. Activating
functions f (x) are shown along the axon’s coordinate x, showing the influence of the electrode separation d. With decreasing d, the depolarized segment of the axon
narrows [i.e., 1x decreases for f (x) > 0] while the local depolarization strength decreases [i.e., f (x) decreases for f (x) > 0]. (B) Advanced model of the tripolar
stimulation with needle voltage electrodes. The spatial distribution of the local electric field E (in dB related to 150 V/m) is shown within the outer ear with the electric
potential 1 V for the red electrode, –1 V for the blue, and 0 V for the green. In fact, the gradient of the electric field [proportional to f (x)] determines the potential
excitation of straight nerves along x aligned typically along auricular vessels (Figure 2).
An optimal electrode position with respect to aVN fibers
and the required penetration depth of needle electrodes for
the percutaneous aVNS are other important optimisation
parameters. The larger is the depth, the easier is the nerve
recruitment, i.e., the lower are the activation thresholds of
auricular axons and the larger is the percentage of activated
axons. In particular, the closer is an electrode to the axon, the
lower is its activation threshold. However, cathodic block with
an inhibited propagation of action impulses can also arise for an
axon residing too close. Therefore, the numerical simulation of
aVNS indicates that the placement of needle electrodes should be
ideally adapted to the individual vessel/nerve wiring of the ear.
Simulations showed that a small distance of about 1 mm should
be kept to vessels/nerves to avoid both subthreshold stimulation
and cathodic block, as well as to avoid potential damage of
vessel/nerves by the chronic electrode presence and to avoid local
bleeding. Please recall that individual aVN fibers can be disclosed
by the transillumination method (Figure 2D).
The temporal pattern and intensity of the applied stimulus
can be optimized with respect to the required fiber recruitment
and the selectivity of stimulation. In terms of selectivity, the
simulation targets are Aβ fibers (responsible for mechanical
sensing) but not Aδ fibers (for pain sensation) so that depolarising
phases of the stimulus should be as short as possible to recruit
easily excitable thick Aβ fibers but not hardly excitable thin
Aδ fibers.
Cathodic stimulation requires lower thresholds than anodic
stimulation given straight geometries of axons residing in a
certain distance from the stimulation electrode. Monophasic
pulses excite more easily than biphasic pulses, especially for
short pulse durations <1 ms (Kaniusas, 2019). Therefore,
cathodic monophasic thresholds are the lowest when individual
nerve fibers are considered. However, if we are interested in
maximizing the total recruitment volume in the ear enclosing
multiple fibers at both anode and cathode, biphasic waveform
seems to be in favor of monophasic waveform. Then numerous
fibers below anode and cathode – disjoint fiber populations –
would experience successive cathodic stimulation (with a low
threshold) and anodic stimulation (with a high threshold). In
particular, the largest recruitment volume results when the
biphasic waveform includes an interphase interval lowering
the stimulation threshold and thus increasing the recruitment
volume even more (Reilly and Diamant, 2011). Of course,
monophasic pulses should also be avoided to prevent the charge
imbalance on the electrode/tissue boundary and thus to avoid
irreversible electrochemical reactions (Kaniusas, 2019).
Another advantage of biphasic waveform is that it may
enhance the total recruitment of fibers excited at their
terminal endings and/or bend regions (Reilly and Diamant,
2011; Kaniusas, 2019) within the ear. Depending on the
orientation of the bend region and/or the terminus of the
neuron, monophasic stimulation leads either to depolarization
or hyperpolarization of an exposed terminus or exposed bend
region close to the electrode. In contrast, biphasic stimulation
leads to depolarization of exposed termini and bend regions
within a single cycle of biphasic waveform under each electrode.
Therefore, biphasic stimulation may favorably enhance the
number of excited disjoint fibers at each electrode due to
the phase reversal.
Figure 4 shows in silico data of aVNS based on tripolar
stimulation which has been shown to provide a more focussed,
spatially selective stimulation of fibers than bipolar or monopolar
stimulation (Kaniusas, 2019). Figure 4A illustrates increasing
sharpness of the spatial stimulation area (in the range of
1 mm) with decreasing separation distance between the three
stimulation electrodes based on the concept of the activating
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function. However, the improved focus in the tripolar stimulation
arrives at the cost of a reduced stimulation efficiency and thus
increased stimulation threshold (Figure 4A). This compromise is
also valid for bipolar stimulation. Figure 4B illustrates maximum
values of the local electric field and of its gradient close to the
needle electrodes due to the electrical point effect (Kaniusas,
2019). The vector field flows in the direction from positive anode
(red electrode) to negative cathode (blue electrode) within the
outer ear, whereas local electric fields decrease along conducting
blood vessels within the ear. While the resulting gradient of the
local electric field along straight axons determines their local
excitation, a constant electric field is sufficient to depolarize
and potentially excite terminal endings and/or bend regions of
auricular axons.
The design of electroceuticals such as aVNS devices can be
assisted by computational models, i.e., functionalized anatomical
models subjected to the discussed coupled electromagnetic
and electrophysiological modeling. These neuro-functionalized
models feature realistic nerve trajectories within detailed
anatomical phantoms (Neufeld et al., 2016). Models facilitate
the exploration and optimisation of various stimulation settings
(e.g., electrode number, shape, and position, as well as
stimulation waveforms) for an efficient recruitment of nerves
while considering the complex heterogeneity of human tissues
and specific anatomy; here extensive sensitivity analyses to
settings changes can be realized. Such models have the
potential to minimize the cost, time efforts, and the number
of involved humans and animals in clinical and experimental
trials, respectively, whereas safety and efficacy of electroceuticals
is increased. Furthermore, functionalized phantoms can be
personalized to arrive at planning and optimization of highly
patient-specific treatment. For instance, such computational
models can be generated with the Sim4Life platform (Neufeld
et al., 2014) for life sciences investigations from Zurich MedTech
AG (Zurich, Switzerland).
PERSONALIZED aVNS
Straightforward open-loop aVNS without any dynamic
adjustment of stimulation parameters may be sufficient
for treatment when the targeted neuromodulatory effects
take a long time to establish, i.e., when there are large time
constants involved. Here a periodic readjustment (e.g., weekly)
of stimulation parameters of aVNS by physicians may be
sufficient to account for these large time constants. However,
for relatively acute treatments, a closed-loop aVNS with an
instantaneous biofeedback – as shown in Figure 5 – may be
more favorable where stimulation parameters are adapted based
on the concurrently recorded physiological impact of aVNS.
A real-time adaptation of the aVNS stimulus is reasonable to
control excitation of aVN according to momentary therapeutic
needs and the actual physiological state of the body.
Each individual patient can be expected to respond uniquely
to aVNS therapy, e.g., findings in Frei and Osorio (2001)
reveal variable effects of VNS on the heart rate (bradycardia
or tachycardia) between patients but consistent within patients.
Therefore, the commonly delivered open-loop aVNS may
significantly limit the aVNS effectiveness unless a proper
adaptivity of aVNS through biofeedback is established within
a patient. In contrast to the open-loop aVNS, the closed-loop
aVNS adapts rapidly to changing conditions and thus offers
a personalized aVNS for a personalized disease control with
increased therapeutic efficiency, raised quality of life, and reduced
severity of side effects. For instance, the closed-loop deep-brain
stimulation in rats showed a reduction in the seizure frequency
by 90% versus only 17% in the open-loop stimulation (Salam
et al., 2015); more examples on the closed-loop stimulation will
follow. In addition, the closed-loop stimulation was shown to
save energy by up to 42% in deep-brain stimulation (Grant
and Lowery, 2012). A systematic overview of concurrent
sensing and stimulation technologies in chronic closed-loop
neuromodulation devices can be found in Stanslaski et al. (2012).
Formation of Biofeedback
The easiest way to close the loop is to provide a simple on-
demand activation of aVNS via subjective biofeedback or via a
biomarker from the patient (e.g., activation via button of magnet
stick in response to upcoming pain). However, besides missing
objective physiological data, elderly and diseased patients cannot
be expected to comply with this self-governed feature for a
variety of reasons (Kampusch et al., 2016). In addition, subjective
biofeedback is possible in specific diseases only (e.g., chronic back
pain) which severity can be individually perceived by the patient.
Thus, an algorithmic-driven activation/adjustment of aVNS
is necessary based on individual physiological biofeedback
provided back to the stimulator (Figure 5) and using different
control models (Romero-Ugalde et al., 2015, 2017). Recording
and analysis of diverse biosignals in response to aVNS can close
the loop and thus allow optimization and personalization of
aVNS therapy. The particular choice of physiological signals
employed as biofeedback depends on the therapeutic/target
function of aVNS. For instance, peripheral blood flow can
be used as a biofeedback signal when targeting peripheral
vasodilation with aVNS, the tonus of the muscle excitation when
targeting involuntary muscle contractions in dystonia, or heart
rate and heart rate variability (HRV) from electrocardiogram
when detecting stressful pain attacks or even suppressing atrial
fibrillation via aVNS activated only once fibrillation is detected
or predicted (Boon et al., 2016) using linear and/or non-linear
methods (Pierzchalski et al., 2011; Nayak et al., 2018).
Instantaneous changes of the heart rate can be viewed as a
phasic expression of central integrative processes in response
to different tonic sensory signals. The frequency of heart rate
changes is subjected to different competing mechanisms, which
range from selective heart frequency entrainment to a specific
physiological process, e.g., to the respiration cycle in terms of
the respiratory sinus arrhythmia (Kaniusas, 2012), to changes
in the gain of the feedback pathway (Fallen et al., 2001). For
instance, VNS in a dog model was switched on when the heart
interval dropped below a certain threshold in order to counteract
arrhythmias which are favored by short heart intervals (Bilgutay
et al., 1968). A closed-loop control of the heart rate was employed
in pigs based on the invasive VNS (Tosato et al., 2006) where the
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FIGURE 5 | Personalized aVNS. (A) The closed-loop aVNS with the physiological biofeedback (e.g., magnitude of the pulse wave or HRV) which is used to control
stimulation parameters of aVNS (e.g., the stimulus strength) in order to adhere to momentary therapeutic needs (e.g., optimal blood perfusion in legs). The
biofeedback can also be used for a temporal synchronization of the applied stimuli with inner body rhythms (e.g., respiratory or cardiac cycle) to interfere
constructively with the dynamics of the body. (B) aVNS of the afferent VN modulates activity of the efferent VN outflow to the heart, whereas the peripheral pulse
wave arriving from the heart can be used as biofeedback to the stimulator of aVNS. (C) Personalized and optimized setting of stimulation needles and their
stimulation patterns for the percutaneous aVNS based on an individualized ear model (Figure 4B) as derived from the transilluminated individual ear (Figure 2D).
Therapy-relevant re-optimization of the stimulation patterns results when the closed-loop aVNS from the panels (A,B) operates. Here the level of the circle’s filling at
each electrode position indicates the local stimulation strength which changes in the course of the closed-loop control.
stimulation frequency was controlled in order to select the right
fiber type to be stimulated.
Not only cardiac-gated aVNS can be realized but also
respiratory-gated aVNS (Kaniusas et al., 2009; Napadow et al.,
2012). The temporal stimulation sequence of aVNS can be even
synchronized with and follow to inner biological rhythms of the
body to increase the coherence between residual body activities
and aVNS effects (Figure 5). For instance, the relevance of the
proper timing of VNS was shown for the induced ischemia and
the following reperfusion in a swine model, with favorable VNS
effects when applied before the reperfusion but not afterward
(Shinlapawittayatorn et al., 2014). In general, VNS should be
applied early in the course of the disease event or process
(Stavrakis and Po, 2015).
Proper selection and targeted processing of physiological
signals as recorded by the sensor (Figure 5) is of crucial
importance for the closed-loop aVNS since the feedback should
contain information about features of physiological reactions
in response to aVNS. Here local biosignals can be used as the
feedback within local control loops, e.g., monitoring the nerve
excitation proximal to the nerve stimulation site (Ward et al.,
2014), as well as global biosignals can input data into global
control loops, e.g., monitoring of heart rate as a global outcome
parameter (Ravan et al., 2017). Local loops can also be used
to optimize the spatial and temporal distribution of the local
stimuli based on personalized ear models while using distributed
multiple needle electrodes in the ear. In contrast to local
loops, global loops cover systemic physiological mechanisms
(e.g., cardiorespiratory and cardiovascular) and show multi-
scale dynamics (Siauciunaite et al., 2018) reflecting various
body rhythms. Multimodal sensing – i.e., simultaneous usage of
different sensing modalities – and/or multiparametric sensing –
i.e., several parameters extracted from a single sensor – require
minimum resources and deliver maximum information content,
and thus can be expected to become powerful tools in the close-
loop aVNS in future.
Figure 5A illustrates the closed-loop aVNS with the
plethysmographic biofeedback, serving not only the controller to
adjust the stimulus pattern but also synchronizing the stimulus.
The target point defines the state to be achieved, e.g., the required
blood perfusion level in the periphery or the targeted level
of HRV. Since the individual human body as the system to
be controlled is never sufficiently known and is subjected to
continuous changes over time, adaptive methods (e.g., machine
learning) should be used to define the controller. Figure 5B
shows a simplified workflow of the closed-loop aVNS with
the heart acting as the system to be controlled. Figure 5C
shows a combination of Figure 5B with an individual ear
model (from Figure 4B) derived from the transilluminated
ear (from Figure 2D) in order to find personalized and
optimized setting of stimulation needles and their stimulation
patterns. Here the closed-loop aVNS re-optimizes continuously
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the stimulation patterns of respective electrodes to reach therapy-
relevant targets.
Therapeutic Applications
An individualized on-demand invasive VNS (controlled by
patients with an active magnet stick) for epileptic treatment was
a benefit for about 50% of patients as related to about 40% with
the non-adaptive VNS (automatic intermittent VNS with inactive
magnet) (Morris, 2003). Here the clinical benefit was defined in
terms of aborted or decreased severity of seizures. In addition,
the seizure improvement was unrelated to seizure frequency,
whereas the on-demand approach provided a favorable reversal
of “learned helplessness” to patients gaining a greater sense of
control over their seizures.
The closed-loop VNS seems to be in favor of the open-loop
VNS while reducing seizure severity (Boon et al., 2015). Here
an increase of the heart rate of at least 20% – indicating an
increased sympathetic outflow associated with ictal discharges
(Eggleston et al., 2014) – was used to detect seizure onset and
then to re-start VNS. Timely and personalized delivery of VNS
in Ravan et al. (2017) was based on increased heart rate and
synchronized brain dynamics to detect seizures for VNS therapy.
The monitored heart rate can be used to close the VNS loop also
in heart failure patients (Guiraud et al., 2016). In particular, the
stimulation frequency, amplitude, pulse width as well as the on-
off time of VNS – either synchronously or asynchronously with
the R-wave of electrocardiogram – can be adjusted in response
to the heart rate (Guiraud et al., 2016). The heart rate was also
used as feedback for VNS affecting the atrioventricular node in
order to reduce the heart rate in atrial fibrillation in a dog model
(Zhang et al., 2002).
Auricular vagus nerve stimulation gated to the exhalation
phase of respiration is suggested to be more efficient in the
activation of NTS (Sclocco et al., 2019) and to improve analgesic
benefits of aVNS while counteracting neuronal adaptation
mechanisms (Napadow et al., 2012), especially in migraine
patients (Garcia et al., 2017). The rationale of this approach is
that natural activity of the efferent and afferent VN is tuned
with respiration. In particular, VN activity is not only directly
modulated by respiration via afferent VN endings in the lungs but
also indirectly modulated via respiratory-related blood pressure
changes (Kaniusas, 2012), namely, via the respiratory-related
recruitment of VN afferents of baroreceptors (Karemaker, 2017).
FUTURE DIRECTIONS
Auricular vagus nerve stimulation is a promising bioelectronic
technology which may serve as an alternative, non-
pharmacological, and neuro-immunomodulatory intervention.
aVNS shows a variety of potential therapeutic applications due to
its systemic effects on the human body (Kaniusas et al., 2019). Its
huge potential, for instance, in chronic pain, warrants manifold
research-guided and clinically related aVNS directions in future.
Founded investigations on the dose-response relationships
in aVNS are sparse (Nonis et al., 2017) regarding relevant
indications (Kaniusas et al., 2019), especially as a function of
stimulation patterns and their parameters that would form a
sound basis for the optimization of aVNS. Research-guided
objectification and optimisation, as well as clinical validation
of stimulation parameters are necessary based on functional
PET/MRI/EEG with improved spatial and time resolution, while
departing from purely empirical aVNS settings used currently
for therapy in humans. In particular, parameters as intensity,
duration, and timing of aVNS (i.e., neuromodulation protocols)
could be optimized in in silico models, and then clinically
validated in humans. The relevance and potential of a co-
stimulation of non-vagal nerve endings in the auricle should be
investigated further, revealing additional mechanisms of action
and potential clinical applications of the electrical auricular
stimulation. Possible synergetic effects of the afferent vagal and
non-vagal stimulation in the cranial and spinal regions should
be examined. Further research is needed to draw conclusions on
efficacy and safety.
Individual optimization of stimulation patterns and their
timing with respect to inner body rhythms – as based on
the closed-loop aVNS – is another fundamental research line.
A reasonable core set of sensor signals and their derived
parameters should be established that best portray aVNS effects,
as well as control algorithms permitting individualization at run
time. Integrated sensors to track therapeutic progress and to
control stimulation parameters are needed. Devices for aVNS
should be integrated in telehealth solutions for a comprehensive
closed-loop therapy management. Therapeutic benefit of the
closed-loop aVNS has to be validated in relation to the open-
loop aVNS.
Potential pairing of aVNS with other rehabilitative stimuli
(Hays, 2015) – e.g., with rehabilitative limb movements in stroke
(Dawson et al., 2015), with acoustical tones in tinnitus (De Ridder
et al., 2013), or with extinction training (Peña et al., 2012) –
should be investigated as promising option to increase efficacy
of aVNS. This pairing is suggested to create targeted and correct
maladaptive plasticity in the brain (Lehtimaki et al., 2012).
Easy-to-assess surrogate parameters and biomarkers should
be derived to differentiate between aVNS responders and non-
responders; e.g., VNS-induced release of norepinephrine was
shown as a marker for seizure suppression (Raedt et al., 2011).
Non-invasive markers of brainstem modulation by aVNS may
include HRV as a potential candidate; e.g., stronger variability
and higher vagal tone were observed in the responder group
to VNS treatment (Liu et al., 2017), as well as event related
potentials (De Taeye et al., 2014), pupillary diameter (Jodoin
et al., 2015), and others (Mertens et al., 2018). Objective surrogate
parameters could be even more useful to select responders than,
for instance, subjective pain scores, especially for late responders
to pain therapy.
CONCLUSION
Auricular vagus nerve stimulation gains importance as a
significant part of bioelectronics medicine in therapy, using
easily controllable digital doses of electrical pulses instead
of pharmaceutical drugs. Electroceuticals for aVNS provides
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promising means to modulate signaling between brain and
periphery and thereby offers a window of opportunity for a
disease-fighting effect on several disorders. aVNS is promising
for systemic treatment, which can be easily interrupted, avoids
severe side-effects, and is well-tolerated by patients. Currently,
robust and validated stimulation protocols that are tuned to
specific targeted physiological responses remain a great challenge
in aVNS engineering. Beyond that a closed-loop aVNS needs to
be established to account for individual physiological variability.
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